Skip to content
DataLookout
Menu

NCT04550494

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 121 versions: 3 with changes below, 47 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion pushed from Jul 27, 2027 to Oct 22, 2027
  2. Minor Study completion date: Jul 14, 2027 to Jul 27, 2027v117
  3. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Enrollment reduced: 36 → 29 participants
    • Primary completion moved earlier from Dec 1, 2026 to Jul 10, 2026
    • Study completion pushed from Dec 1, 2026 to Jul 14, 2027
    v116
  • Minor: routine updates

Endpoints

Primary

Percent of patients who demonstrate simultaneous Rad51 activation
Timeframe: At cycle 2 day 1

Secondary (1)

Overall response rate

Arms and interventions

Treatment (talazoparib)Experimental

Patients receive talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and blood sample collection as well as CT scan or MRI throughout the study.

Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging

Drugs: Talazoparib

Sites

4 sites in 1 country